Vivet Therapeutics

Thomas Daniel-Robin, Business Development Director

April 20 | 2:45pm | Gaudi 2 Ballroom

Paris, France


In-Person Presentation

Vivet Therapeutics is a clinical-stage biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases. Vivet is building a diversified gene therapy pipeline based on novel recombinant adeno-associated virus technologies developed through its partnerships with, and exclusive licenses from, the Fundación para la Investigación Médica Aplicada (FIMA), a not-for-profit foundation at the Centro de Investigación Medica Aplicada, University of Navarra based in Pamplona, Spain. Vivet’s lead program, VTX-801, currently under IND clinical development with the GATEWAY clinical trial, is a novel investigational gene therapy for Wilson Disease which has been granted Orphan Drug Designation (ODD) by the FDA and the European Commission. Vivet’s second gene therapy product, VTX-803 for PFIC3, received U.S. and European ODD in May 2020. Vivet is supported by international life science investors including Novartis Venture Fund, Roche Venture Fund, HealthCap, Pfizer, Columbus Venture Partners, Ysios Capital, Kurma Partners, and Idinvest Partners.

By using this website you agree to accept our Privacy Policy and Terms & Conditions